Related Experiment Video
Updated: Feb 23, 2026

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
Anti-proliferative, pro-apoptotic and anti-invasive effect of EC/EV system in human osteosarcoma
Francesca Punzo1,2, Chiara Tortora1,2, Daniela Di Pinto1
1Department of Women, Child and General and Specialist Surgery, Second University of Naples, 80138 Naples, Italy.
Abstract:
Osteosarcoma is the most common and aggressive bone tumor in children. The Endocannabinoid/Endovanilloid system has been proposed as anticancer target in tumor of different origins. This system is composed of two receptors (CB1 and CB2), the Transient Potential Vanilloid 1 (TRPV1) channel and their ligands and enzymes. CB1 is expressed mainly in central nervous system while CB2 predominantly on immune and peripheral cells. We investigated the effects of JWH-133 (CB2 agonist) and RTX (TRPV1 agonist) in six human Osteosarcoma cell lines: MG-63, U-2OS, MNNG/HOS, Saos-2, KHOS/NP, Hs888Lu, by Apoptosis and Migration-Assay. We also compared the effects of these compounds on Caspase-3, AKT, MMP-2 and Notch-1 regulation by Q-PCR and Western Blotting. We observed an anti-proliferative, pro-apoptotic, anti-invasive effect. Our results show that both CB2 stimulation and TRPV1 activation, in different Osteosarcoma cell lines, can act on the same pathways to obtain the same effect, indicating the Endocannabinoid/Endovanilloid system as a new therapeutic target in Osteosarcoma.
Insights
Targeting the Endocannabinoid/Endovanilloid system shows promise for treating osteosarcoma. CB2 receptor stimulation and TRPV1 channel activation reduced tumor cell proliferation and invasion in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Osteosarcoma is a highly aggressive pediatric bone cancer.
- The Endocannabinoid/Endovanilloid system, including CB1, CB2 receptors, and TRPV1 channels, is a potential anticancer target.
- Understanding this system's role in osteosarcoma is crucial for developing new therapies.
Purpose of the Study:
- To investigate the therapeutic potential of CB2 receptor agonist (JWH-133) and TRPV1 channel agonist (RTX) in human osteosarcoma cell lines.
- To evaluate the effects of these agonists on osteosarcoma cell proliferation, apoptosis, and invasion.
- To analyze the impact of CB2 and TRPV1 activation on key molecular pathways involved in cancer progression.
Main Methods:
- Utilized six human osteosarcoma cell lines (MG-63, U-2OS, MNNG/HOS, Saos-2, KHOS/NP, Hs888Lu).
- Assessed apoptosis and cell migration using specific assays.
- Quantified gene and protein expression of Caspase-3, AKT, MMP-2, and Notch-1 via Q-PCR and Western Blotting.
Main Results:
- Both JWH-133 (CB2 agonist) and RTX (TRPV1 agonist) demonstrated significant anti-proliferative and pro-apoptotic effects.
- Treatment with these agonists led to a marked reduction in cancer cell invasion.
- CB2 stimulation and TRPV1 activation modulated Caspase-3, AKT, MMP-2, and Notch-1 pathways, achieving similar outcomes.
Conclusions:
- The Endocannabinoid/Endovanilloid system presents a viable therapeutic target for osteosarcoma.
- Targeting CB2 receptors or TRPV1 channels can inhibit osteosarcoma progression through shared molecular pathways.
- These findings support further research into cannabinoid and vanilloid-based therapies for osteosarcoma.
Related Concept Videos
Mesenchymal Stem Cells
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

